Navigation Links
Former FDA Commissioner Joins Bexion Pharmaceuticals Board

COVINGTON, Ky., Jan. 6, 2011 /PRNewswire/ -- Bexion Pharmaceuticals, LLC announced today that it has added Lester Crawford, D.V.M., and Ph.D. to its Board of Directors.

Dr. Crawford has had a distinguished career in the public and private sectors as well as academia. Over ten years of his career were spent at the Food and Drug Administration (FDA) serving in a variety of pivotal roles and culminating in his appointment as FDA Commissioner.

Prior to FDA, Dr. Crawford served in many capacities at the University of Georgia, including chair of the Department of Physiology and Pharmacology and at Georgetown University where he was director of the Center for Food and Nutrition Policy. Dr. Crawford has been an expert advisor to the World Health Organization, the Singapore FDA and the U. S. Academy of Sciences. He is currently a Partner and Senior Science Advisor at Policy Directions, Inc.

"We are excited and privileged to have Dr. Crawford join our Board of Directors," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Dr. Crawford brings us important insights on regulatory and industry issues that are vital as we approach an IND submission in 2011, and anticipated clinical trials", added Dr. Takigiku.

"I am especially pleased to join Bexion's Board of Directors," added Dr. Crawford. "I am looking forward to sharing my experience over a long career to help Bexion reach its goal of providing first-in-class, innovative technology to cancer patients worldwide."

About Bexion Pharmaceuticals:Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutic, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit contact:Margaret M. van GilseVP, Investor RelationsBexion Pharmaceuticals, LLC632 Russell StreetCovington, KY 41011Phone: (513)

SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 15th ... are handling security in light of the recent terrorist attacks in Paris, other cities ... stop an attack from reaching U.S. soil. Especially around special events that may be ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
Breaking Medicine News(10 mins):